Zymeworks (ZYME) Competitors

Zymeworks (NYSE:ZYME) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk, community ranking and dividends.

Is ZYME or RARE more profitable?

Ultragenyx Pharmaceutical has a net margin of -101.60% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-182.75%	-23.00%	-18.04%
Ultragenyx Pharmaceutical	-101.60%	-193.80%	-38.15%

Which has more volatility and risk, ZYME or RARE?

Zymeworks has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.

Do insiders & institutionals have more ownership in ZYME or RARE?

92.9% of Zymeworks shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 1.9% of Zymeworks shares are held by company insiders. Comparatively, 5.5% of Ultragenyx Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Do analysts rate ZYME or RARE?

Zymeworks presently has a consensus price target of $21.00, suggesting a potential upside of 75.88%. Ultragenyx Pharmaceutical has a consensus price target of $90.93, suggesting a potential upside of 156.80%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90
Ultragenyx Pharmaceutical	0 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.93

Which has better earnings and valuation, ZYME or RARE?

Zymeworks has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Zymeworks is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$93.38M	8.90	-$118.67M	-$1.49	-8.01
Ultragenyx Pharmaceutical	$590.69M	5.67	-$569.18M	-$5.88	-6.02

Does the MarketBeat Community believe in ZYME or RARE?

Ultragenyx Pharmaceutical received 543 more outperform votes than Zymeworks when rated by MarketBeat users. Likewise, 77.54% of users gave Ultragenyx Pharmaceutical an outperform vote while only 67.89% of users gave Zymeworks an outperform vote.

Company	Underperform	Outperform
Zymeworks	Outperform Votes 296 67.89%	Underperform Votes 140 32.11%
Ultragenyx Pharmaceutical	Outperform Votes 839 77.54%	Underperform Votes 243 22.46%

Does the media refer more to ZYME or RARE?

In the previous week, Zymeworks and Zymeworks both had 16 articles in the media. Ultragenyx Pharmaceutical's average media sentiment score of 1.34 beat Zymeworks' score of 1.04 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	15 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Ultragenyx Pharmaceutical beats Zymeworks on 11 of the 18 factors compared between the two stocks.